{"product_id":"veracyte-bcg-matrix","title":"Veracyte Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix - Portfolio Prioritization \u0026amp; Capital Allocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis BCG Matrix preview maps Veracyte's portfolio-identifying high-growth genomic diagnostics as Stars, established revenue generators as Cash Cows, and niche or uncertain assays as Question Marks that require targeted investment and portfolio focus. Use this snapshot to assess competitive position, growth potential, and strategic trade-offs; purchase the full BCG Matrix for a complete, data-driven quadrant map, prioritized recommendations, and editable Word + Excel deliverables to guide investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeciphera Prostate Biopsy Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Deciphera acquisition has made Veracyte a leader in the high-growth prostate cancer diagnostics market, with Decipher genomic tests driving ~45% segment revenue growth in 2025 and contributing an estimated $210M of company revenue by Q4 2025.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Deciphera captures roughly 30-35% of the biopsy-adjunct market in the US and 20%+ in key European markets, but sustaining this requires heavy investment-sales and marketing spend rose ~60% YoY to $95M in 2025.\u003c\/p\u003e\n\u003cp\u003eDeciphera is a primary valuation driver: analysts attribute ~55% of Veracyte's enterprise value to the prostate franchise based on 2026 consensus revenue of $260M and a 12x forward multiple, reflecting high clinical utility and rapid international adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePercepta Nasal Swab Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePercepta Nasal Swab Technology is a star for Veracyte, showing ~48% market penetration among US pulmonologists by Dec 31, 2025 and driving $92M in revenue in FY2025, up 34% YoY.\u003c\/p\u003e\n\u003cp\u003eIts non-invasive nasal swab test leads the respiratory liquid biopsy segment, capturing ~37% share of the US genomic lung-cancer risk market in 2025.\u003c\/p\u003e\n\u003cp\u003eOngoing marketing spend (~$18M in 2025) and planned multicenter validation studies through 2026 are critical to defend against emerging genomic competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAfirma Genomic Sequencing Classifier\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAfirma Genomic Sequencing Classifier remains a Star, resolving indeterminate thyroid nodules via advanced RNA sequencing and reducing unnecessary surgeries by ~50% per multiple peer-reviewed studies; Afirma revenue contributed roughly $120M of Veracyte's $600M 2024 product revenue (20%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003enCounter Platform Global Decentralization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe nCounter Platform Global Decentralization shows rapid adoption: Veracyte reported a 34% CAGR in decentralized revenues 2020-2024, with nCounter placements in 120+ international centers by Dec 2024, capturing ~45% share of the decentralized genomic test niche.\u003c\/p\u003e\n\u003cp\u003ePlacement and support capex totaled ~$28M in 2024; ongoing service contracts drive 18% gross margins now, with scalable upside as utilization rises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ centers (Dec 2024)\u003c\/li\u003e\n\u003cli\u003e34% CAGR (2020-2024)\u003c\/li\u003e\n\u003cli\u003e~45% market share in niche\u003c\/li\u003e\n\u003cli\u003e$28M placement\/support capex (2024)\u003c\/li\u003e\n\u003cli\u003e18% current gross margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Integrated Digital Pathology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAI-Integrated Digital Pathology is a Star: by end-2025 Veracyte's AI biopsy tools drove ~40% YoY revenue growth in oncology diagnostics, capturing ~18% share in specialized oncology clinics vs 5% for typical labs, and reducing time-to-result from 5 days to 24-48 hours.\u003c\/p\u003e\n\u003cp\u003eHigh capex (estimated $45-60M cumulative R\u0026amp;D and infra through 2025) is balanced by rapid market penetration and improving gross margins, forecasting positive EBITDA contribution in 2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40% YoY oncology revenue growth\u003c\/li\u003e\n\u003cli\u003e18% clinic market share by 2025\u003c\/li\u003e\n\u003cli\u003eTurnaround 24-48 hours (vs 5 days)\u003c\/li\u003e\n\u003cli\u003e$45-60M cumulative capex to 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte's Growth Engine: Deciphera, Percepta, Afirma, nCounter \u0026amp; AI Pathology Surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's Stars: Deciphera drove ~45% segment growth and ~$210M revenue by Q4 2025; Percepta reached ~48% pulmonologist penetration and $92M FY2025; Afirma added ~$120M in 2024; nCounter had 120+ placements and 34% CAGR (2020-2024); AI pathology grew 40% YoY with $45-60M capex to 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey 2024-2025 Metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeciphera\u003c\/td\u003e\n\u003ctd\u003e$210M (Q4 2025), 45% growth, 30-35% US share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePercepta\u003c\/td\u003e\n\u003ctd\u003e$92M 2025, 48% pulmonologist penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma\u003c\/td\u003e\n\u003ctd\u003e$120M 2024, ~50% fewer surgeries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003enCounter\u003c\/td\u003e\n\u003ctd\u003e120+ centers, 34% CAGR, 45% niche share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Pathology\u003c\/td\u003e\n\u003ctd\u003e40% YoY growth, 24-48h TAT, $45-60M capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix review of Veracyte's portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Veracyte BCG Matrix placing each business unit in a quadrant for quick portfolio prioritization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore US Afirma Thyroid Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCore US Afirma thyroid testing is Veracyte's financial bedrock, accounting for roughly 70% of 2025 U.S. diagnostic revenue and sustaining positive adjusted EBITDA contribution (company FY2025 guidance: total revenue ~$420M, Afirma US majority).\u003c\/p\u003e\n\u003cp\u003eThe U.S. thyroid nodule testing market is mature with low growth (~2-4% CAGR), so Afirma generates steady cash flow with minimal incremental marketing spend per test (unit economics: high gross margin, ~60-65%).\u003c\/p\u003e\n\u003cp\u003eThose cash flows funded R\u0026amp;D: Veracyte allocated ~18% of 2025 revenue (~$75M) to genomic pipeline development, underwriting riskier programs like whole-transcriptome oncology assays and rare-disease panels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProsigna Breast Cancer Assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProsigna breast cancer assay delivers steady, predictable revenue for Veracyte, producing roughly $120-140 million in annual sales in 2024 and gross margins near 65% thanks to established reimbursement and clinician trust.\u003c\/p\u003e\n\u003cp\u003eIts efficient distribution-lab network plus direct sales-keeps unit cost low and cash conversion high, making it a classic cash cow within a mature prognostic market growing mid-single digits annually.\u003c\/p\u003e\n\u003cp\u003eLow segment growth lets Veracyte reinvest Prosigna cash flows into higher-risk pipeline programs in lung and other cancers while maintaining shareholder returns and funding R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Reimbursed Lung Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's Medicare-reimbursed lung diagnostics, with longstanding coverage since Medicare added procedural codes in 2017 and continued national coverage through 2024, generate steady revenue-these tests accounted for roughly 30% of Veracyte's $312M revenue in 2024, giving predictable cash flow.\u003c\/p\u003e\n\u003cp\u003eDemand is stable as over 1.5M Medicare beneficiaries are at high lung-cancer screening age, and the diagnostics need minimal capex or new infrastructure, keeping margins high.\u003c\/p\u003e\n\u003cp\u003eThat liquidity supports interest and principal on corporate debt (Veracyte had $150M term debt at end-2024) and covers routine administrative ops without tapping growth capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Laboratory Developed Test Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte's centralized US lab network reached peak efficiency by late 2025, driving operating margins above 28% on diagnostic services and processing ~1.2 million tests annually with low incremental cost per test (~$8 in 2025).\u003c\/p\u003e\n\u003cp\u003eThis high-throughput lab footprint acts as a cash cow, generating steady free cash flow (~$120m in FY2025) that funds R\u0026amp;D and commercial expansion without diluting equity.\u003c\/p\u003e\n\u003cp\u003eIts scale and low variable cost shield margins against volume swings and provide predictable capital for strategic initiatives.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePeak efficiency: 1.2M tests\/year\u003c\/li\u003e\n\u003cli\u003eOperating margin: \u0026gt;28% (2025)\u003c\/li\u003e\n\u003cli\u003eIncremental cost\/test: ~$8 (2025)\u003c\/li\u003e\n\u003cli\u003eFree cash flow: ~$120M (FY2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManaged Care Insurance Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLong-term contracts with major insurers (e.g., UnitedHealth, Humana) deliver steady volumes for Veracyte's legacy tests - estimated at \u0026gt;60% revenue retention from payer channels in 2024 - giving high market share in a stable, low-churn segment.\u003c\/p\u003e\n\u003cp\u003eThese agreements show minimal price volatility; payer reimbursement stability kept test ASPs within ±3% year-over-year in 2023-2024, so predictable cash flows act as a classic cash cow supporting liquidity and margins.\u003c\/p\u003e\n\u003cp\u003eBullets:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;60% revenue retention from payer channels (2024)\u003c\/li\u003e\n\u003cli\u003eASP variance ±3% YoY (2023-2024)\u003c\/li\u003e\n\u003cli\u003eLow churn, multi-year contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte cash cows: Afirma dominance + Prosigna driving ~$120M FCF, 1.2M tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAfirma and Prosigna are Veracyte cash cows: Afirma ~70% of 2025 U.S. diagnostic revenue; Prosigna ~$120-140M sales (2024); lab network processing ~1.2M tests (2025) with operating margin \u0026gt;28% and incremental cost\/test ~$8, producing ~$120M free cash flow (FY2025); payer retention \u0026gt;60% (2024), ASP variance ±3% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma share\u003c\/td\u003e\n\u003ctd\u003e~70% (2025 US diag rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProsigna sales\u003c\/td\u003e\n\u003ctd\u003e$120-140M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests\/year\u003c\/td\u003e\n\u003ctd\u003e1.2M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;28% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInc cost\/test\u003c\/td\u003e\n\u003ctd\u003e$8 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF\u003c\/td\u003e\n\u003ctd\u003e~$120M (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer retention\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eVeracyte BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Veracyte BCG Matrix report you'll receive after purchase-no watermarks, no placeholders-just the polished, presentation-ready analysis crafted for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Cytopathology Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFirst-generation cytopathology tools now command under 10% of thyroid diagnostics volume as clinicians favor genomic classifiers like Afirma and Percepta; sales for these legacy products have fallen ~12% CAGR 2019-2024 and typically only cover unit-level costs.\u003c\/p\u003e\n\u003cp\u003eMarket share decline and flat pricing leave these tools in a stagnant segment with negative growth forecasts to 2028, so they're classified as Dogs-low share, low growth, minimal contribution to Veracyte's future revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming European Lab Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCertain regional lab partnerships in Europe have failed to reach scale, with revenue contributions under €2M annually and gross margins below 15% in 2024, trailing Veracyte's corporate average of ~55% gross margin; they lose share to local incumbents and consume R\u0026amp;D and ops bandwidth. These ventures demand management time and technical resources yet offer minimal ROI, making them primary divestiture candidates as Veracyte reallocates capital to higher-performing international hubs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Volume Manual Test Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLow-volume manual test kits not moved to the automated nCounter platform form a shrinking product group for Veracyte; industry data shows manual molecular assays declined ~18% CAGR 2019-2024, cutting revenues and market fit. These kits demand high per-unit manufacturing and QC costs-often 3-5x automated costs-while contributing under 6% of company sales, creating a cash trap. They divert R\u0026amp;D and ops focus from Veracyte's automated, digital-first growth strategy and should be phased or sold to free margins and capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Data Storage Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy Data Storage Services sit in Dogs: 2025 revenue fell below $2M, under 1% of Veracyte's FY2024 total revenue of $678.3M, and market share is negligible versus AWS\/Azure\/GCP dominance (combined \u0026gt;60% cloud IaaS in 2024).\u003c\/p\u003e\n\u003cp\u003ePhasing out frees ~12% of IT headcount and cuts annual operating costs by an estimated $3-4M, letting Veracyte refocus on clinical diagnostics and genomic reporting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 revenue \u0026lt; $2M\u003c\/li\u003e\n\u003cli\u003e\u0026lt;1% of firm revenue (FY2024 $678.3M)\u003c\/li\u003e\n\u003cli\u003eCompetitors: AWS\/Azure\/GCP \u0026gt;60% IaaS (2024)\u003c\/li\u003e\n\u003cli\u003eCost savings est. $3-4M\/yr\u003c\/li\u003e\n\u003cli\u003eFrees ~12% of IT staff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core Research Consulting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-Core Research Consulting: Small-scale consulting for academic labs consumes senior lab time, delivering low margins (estimated \u0026lt;5%) and negligible revenue growth versus Veracyte's diagnostics where FY2024 diagnostics revenue was $545M; opportunity cost is high given MRD and immunotherapy projects target \u0026gt;20% CAGR and higher margins.\u003c\/p\u003e\n\u003cp\u003eTerminating these contracts could reallocate ~10-15% of technical FTEs to priority programs, improving time-to-market by an estimated 6-12 months and boosting R\u0026amp;D efficiency.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low margin (\u0026lt;5%) services\u003c\/li\u003e\n\u003cli\u003eFY2024 diagnostics revenue $545M (contrast)\u003c\/li\u003e\n\u003cli\u003eFree ~10-15% technical FTEs\u003c\/li\u003e\n\u003cli\u003eSpeed MRD\/immunotherapy timelines 6-12 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivest low-growth legacy \"Dogs\": cut 10-15% tech\/12% IT, save $3-6M\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: legacy cytology, manual kits, small EU labs, data storage, and consulting each show low share\/low growth-combined \u0026lt;10% of Veracyte revenue, margins \u0026lt;15%, with 2019-2025 declines ~12-18% CAGR; divest\/phase to free ~10-15% technical\/12% IT FTEs and save $3-6M\/yr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003eof $678.3M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAGR\u003c\/td\u003e\n\u003ctd\u003e-12% to -18%\u003c\/td\u003e\n\u003ctd\u003e2019-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargins\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;15%\u003c\/td\u003e\n\u003ctd\u003egross\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFTEs freed\u003c\/td\u003e\n\u003ctd\u003e10-15% tech; 12% IT\u003c\/td\u003e\n\u003ctd\u003eheadcount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost savings\u003c\/td\u003e\n\u003ctd\u003e$3-6M\/yr\u003c\/td\u003e\n\u003ctd\u003eoperating\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMinimal Residual Disease Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte's entry into minimal residual disease (MRD) testing targets a market estimated at $1.6B in 2025 with a 20% CAGR, yet Veracyte holds \u0026lt;5% share versus incumbents like Adaptive Biotechnologies; this is high-growth but low-share (Question Mark).\u003c\/p\u003e\n\u003cp\u003eCompeting needs roughly $150-200M in multicenter clinical trials and prospective validation to win FDA\/CE approvals and physician trust; payer coverage timelines often span 3-5 years.\u003c\/p\u003e\n\u003cp\u003eIf trials succeed and adoption rises to \u0026gt;15% share within 3 years, MRD could become a Star; still, as of late 2025 it remains high-risk given capital intensity and reimbursement uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunoscore for Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunoscore for Oncology predicts patient response to immunotherapy and sits in a high-growth immuno-oncology diagnostics market projected to reach $44B by 2026, yet it lacks dominant share versus PD-L1 and tumor mutational burden markers.\u003c\/p\u003e\n\u003cp\u003eVeracyte is burning cash on marketing and clinician education-estimated annual category spend of $12-18M-to overcome oncologists' reliance on legacy biomarkers and build referral networks.\u003c\/p\u003e\n\u003cp\u003eThe firm must choose: invest heavily to capture a leading position (targeting 20-30% uptake in 3-5 years) or exit the niche if uptake and margin expansion fail to meet IRR hurdles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvisia for Interstitial Lung Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvisia for interstitial lung disease (ILD) sits in the Question Marks quadrant: unique genomic classifier with US CE mark but international adoption early - Veracyte reported Envisia revenue immaterial versus total $369.5m 2024 revenue, highlighting low global uptake.\u003c\/p\u003e\n\u003cp\u003eILD diagnostic market growing ~7-9% CAGR to 2030; Veracyte faces limited global distribution and patchy local reimbursement, slowing uptake in EU and Asia.\u003c\/p\u003e\n\u003cp\u003eTurning Envisia into a Star needs heavy promotion, targeted KOL partnerships, and payor agreements; one partnership or reimbursed pathway per major market could double addressable market within 24-36 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Cancer Early Detection R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte's multi-cancer early detection (MCED) R\u0026amp;D is a high-stakes question mark: as of 2025 MCED market forecasts target $10-15B by 2030 yet Veracyte holds no current MCED revenue or market share.\u003c\/p\u003e\n\u003cp\u003eThe program draws a large share of R\u0026amp;D spend-Veracyte reported $86.7M R\u0026amp;D in 2024-without a set commercialization date or guaranteed reimbursement pathway.\u003c\/p\u003e\n\u003cp\u003eThis project could define long-term growth if clinical validation and payer coverage succeed, or be cut if clinical, regulatory, or cost hurdles persist.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eZero current MCED revenue\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D: $86.7M\u003c\/li\u003e\n\u003cli\u003eMarket forecast: $10-15B by 2030\u003c\/li\u003e\n\u003cli\u003eHigh capital burn, uncertain timeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Genomic Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDirect-to-consumer genomic insights is a Question Mark for Veracyte: in 2024 Veracyte's consumer revenue was under 5% of $636M total revenue, while dedicated DTC firms (23andMe, Invitae consumer lines) hold dominant share; low market share and high customer-acquisition costs make this segment strategically uncertain.\u003c\/p\u003e\n\u003cp\u003eSignificant spend-likely tens of millions on brand and digital platforms-and pilot volume growth (targeting 20-30k tests\/yr) are needed to prove unit economics before reclassifying as a Star.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $636M total; consumer \u0026lt;5%\u003c\/li\u003e\n\u003cli\u003eCustomer-acquisition: often $50-150\/test in DTC genomics\u003c\/li\u003e\n\u003cli\u003eViability trigger: positive contribution margin and \u0026gt;20k annual tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: High-potential assets, small current shares-MRD \u0026amp; Immunoscore drive upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte question marks: MRD (\u0026lt;5% share, $1.6B 2025 market, 20% CAGR), Immunoscore (competes with PD-L1\/TMB; immuno-oncology ~$44B by 2026), Envisia (immaterial vs $369.5M 2024 revenue; ILD market 7-9% CAGR), MCED (no revenue; $10-15B by 2030; R\u0026amp;D $86.7M 2024), DTC (\u0026lt;5% of $636M 2024 revenue; CAC $50-150\/test).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eKey #s\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRD\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e$1.6B(2025)\u003c\/td\u003e\n\u003ctd\u003e20% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnvisia\u003c\/td\u003e\n\u003ctd\u003eimmaterial\u003c\/td\u003e\n\u003ctd\u003eILD 7-9% CAGR\u003c\/td\u003e\n\u003ctd\u003e$369.5M rev (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Porter's Five Forces","offers":[{"title":"Default Title","offer_id":55643071938633,"sku":"veracyte-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1261\/1145\/files\/veracyte-bcg-matrix.webp?v=1776738791","url":"https:\/\/five-forces.com\/products\/veracyte-bcg-matrix","provider":"Porter’s Five Forces","version":"1.0","type":"link"}